<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02958462</url>
  </required_header>
  <id_info>
    <org_study_id>16-004173</org_study_id>
    <nct_id>NCT02958462</nct_id>
  </id_info>
  <brief_title>Pre-myeloid Cancer and Bone Marrow Failure Clinic Study</brief_title>
  <official_title>Pre-myeloid Cancer and Bone Marrow Failure Clinic Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of genomics and functional translational studies is to identify and diagnose patients&#xD;
      with precursor features of myeloid neoplasms and inherited bone marrow failure syndromes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pre-myeloid cancer and bone marrow failure clinic is an individualized medicine clinic&#xD;
      conceptualized for the early detection of myeloid malignancies such as, myelodysplastic&#xD;
      syndromes (MDS), myeloproliferative neoplasms (MPN), MDS/MPN overlap syndromes and acute&#xD;
      myeloid leukemia (AML). Using next-generation sequencing technologies, clonal hematopoietic&#xD;
      stem cell changes can be detected early on in myeloid malignancies. These changes are&#xD;
      currently classified as follows:&#xD;
&#xD;
        1. Idiopathic cytopenias of unclear significance (ICUS).&#xD;
&#xD;
        2. Clonal cytopenias of unclear significance (CCUS).&#xD;
&#xD;
        3. Clonal hematopoiesis of indeterminate prognosis (CHIP).&#xD;
&#xD;
        4. Bone marrow failure syndromes with risk for clonal myeloid transformation.&#xD;
&#xD;
        5. Familial/Germline syndromes with increased risk for myeloid malignancies.&#xD;
&#xD;
      This clinic blends next-generation sequencing technologies with functional studies to help&#xD;
      identify, prognosticate and define management plans; including early intervention strategies,&#xD;
      for affected patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects whose cytopenias are persistent or progressive over the course of the 5 year study</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who have evolved to myelodspalstic syndrome (MDS) or acute myeloid leukemia (aml) over the course of the five year study</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Myeloid Malignancy</condition>
  <condition>Inherited Bone Marrow Failure Syndrome</condition>
  <condition>Clonal Expansion</condition>
  <condition>Cytopenia</condition>
  <arm_group>
    <arm_group_label>Potential Premyeloid Cancer or Bone Marrow Failure Patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Follow up provided for patients tested using Next Generation Sequencing (NGS) and other relevant functional studies</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>follow up</intervention_name>
    <arm_group_label>Potential Premyeloid Cancer or Bone Marrow Failure Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with:&#xD;
&#xD;
          -  Idiopathic cytopenias of unclear significance (ICUS)&#xD;
&#xD;
          -  Clonal hematopoiesis of indeterminate significance (CHIP)&#xD;
&#xD;
          -  Age related clonal hematopoiesis (ARCH)&#xD;
&#xD;
          -  Clonal cytopenias of unclear significance (CCUS)&#xD;
&#xD;
          -  Marrow failure syndromes with myeloid malignancy predisposition- telomere dysfunction,&#xD;
             chromosomal breakage disorders, etc.&#xD;
&#xD;
          -  Germ line inherited syndromes with risk for malignant transformation&#xD;
&#xD;
          -  Low Risk Myelodysplastic Syndromes (MDS)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are unable to understand and sign the Informed Consent Form&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mrinal S Patnaik, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caleb Hammel, BSc</last_name>
    <phone>507-538-6691</phone>
    <email>hammel.caleb@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 4, 2016</study_first_submitted>
  <study_first_submitted_qc>November 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2016</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Mrinal S. Patnaik, M.B.B.S.</investigator_full_name>
    <investigator_title>Associate Professor of Medicine, Assistant Professor of Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Marrow Failure Disorders</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
    <mesh_term>Congenital Bone Marrow Failure Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

